# Spyre Completes Trio of Phase 2 Wins in Inflammatory Bowel Disease with IL-23 Antibody

Spyre Biotech has reported a phase 2 clinical win for its anti-IL-23 antibody in ulcerative colitis. This result completes a set of three phase 2 successes for the company’s inflammatory bowel disease (IBD) program.

The company is pursuing a three-pronged strategy for IBD. According to the report, this approach continues to pay off. The anti-IL-23 antibody is the latest candidate to show positive phase 2 data, adding to earlier wins from two other programs in Spyre’s pipeline.

The exact details of the trial results, including patient numbers and efficacy measures, were not disclosed in the report. However, the outcome is significant for Spyre as it validates the broader platform for treating IBD.

IBD, which includes ulcerative colitis and Crohn’s disease, is a chronic inflammatory condition of the gastrointestinal tract. Current treatments often lose effect over time or carry side effects. New therapies that target specific immune pathways, such as IL-23, offer more options for patients who do not respond to existing biologics.

Spyre’s success across three different mechanisms suggests the company is building a diversified portfolio within IBD. That could reduce clinical risk and create multiple avenues to market. The latest phase 2 win also strengthens Spyre’s position as it moves toward later-stage development.

Source: [original report](https://www.fiercebiotech.com/biotech/spyre-snags-phase-2-win-il-23-antibody-round-ulcerative-colitis-program)